What is the FIB‑4 score, how is it calculated, and what do its results indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

FIB-4 Score: Definition, Calculation, and Clinical Interpretation

The FIB-4 (Fibrosis-4) index is a simple, nonproprietary blood-based score that serves as the first-line tool for assessing advanced liver fibrosis risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and other chronic liver diseases. 1

How FIB-4 is Calculated

The formula is: FIB-4 = [age (years) × AST (U/L)] / [platelet count (10⁹/L) × √ALT (U/L)] 1

This calculation requires only four readily available parameters:

  • Patient's age in years
  • AST (aspartate aminotransferase) level
  • ALT (alanine aminotransferase) level
  • Platelet count

The score can be calculated at bedside using free online calculators, making it highly accessible in primary care settings 2.

Interpretation of Results

Low Risk: FIB-4 <1.3 (or <2.0 if age >65 years)

  • Reliably excludes advanced fibrosis with negative predictive value ≥90% 3
  • These patients are at low risk for metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis
  • Recommend reassessment every 1-3 years 1
  • No further immediate evaluation needed 3

Critical caveat: Despite the high negative predictive value, FIB-4 will miss approximately 10% of individuals with advanced fibrosis 1. Clinicians must remain vigilant for clinical signs of progression.

Indeterminate Risk: FIB-4 1.3-2.67

This range represents 30-40% of tested patients and requires additional assessment 3. Two management options exist 1:

Option A (preferred for values closer to 2.67 or high-risk conditions):

  • Proceed directly to liver elastography (e.g., vibration-controlled transient elastography/VCTE) as second-tier testing
  • Alternative: Enhanced Liver Fibrosis (ELF) blood test if elastography unavailable

Option B:

  • Implement 1-year intervention with lifestyle modification and intensified cardiometabolic risk factor management
  • Retest FIB-4 after 1 year
  • If still elevated, proceed to elastography

High Risk: FIB-4 >2.67

  • Indicates high risk for advanced fibrosis with positive predictive value of 60-80% 3
  • Refer to hepatology for liver stiffness measurement or liver biopsy to confirm fibrosis stage 3
  • These patients require diagnostic work-up and management plan for liver-related outcomes 1

Age-Specific Considerations

For patients >65 years old, use modified thresholds 3, 1:

  • Lower cutoff changes from 1.3 to 2.0 for ruling out advanced fibrosis
  • This adjustment is critical because age is a component of the FIB-4 formula and can lead to false positives in elderly populations 1

The 2024 EASL-EASD-EASO guidelines emphasize that FIB-4's ability to detect fibrosis is limited in the elderly and in individuals with type 2 diabetes 1.

Clinical Performance and Limitations

Diagnostic accuracy:

  • AUROC approximately 0.77 for predicting fibrosis stages ≥F3 1
  • Best at distinguishing patients with versus without advanced fibrosis (F3 or higher) 3
  • May miss some patients with F2 fibrosis at initial assessment, though these should be detected during future assessments as they progress 3

Key limitations to recognize:

  • Limited accuracy in the intermediate range (1.3-2.67) 1
  • Can result in high number of false positives, especially in lower prevalence populations 1
  • Performs poorly in low-risk populations 1
  • Reduced performance in patients with type 2 diabetes 1
  • Should not be used as a single test in primary care settings when specifically validated for individuals younger than 35 years 1

Prognostic Value

FIB-4 correlates with clinical outcomes beyond just fibrosis staging 3. High FIB-4 values have been associated with:

  • All-cause mortality
  • Liver-related outcomes
  • Cardiovascular mortality 4
  • Major adverse liver outcomes 4

This makes FIB-4 not just a diagnostic tool but also a prognostic marker for identifying patients at risk of developing liver-related events 1.

Recommended Clinical Pathway

The 2024 EASL-EASD-EASO guidelines recommend FIB-4 testing in 1:

  1. Patients with type 2 diabetes
  2. Patients with abdominal obesity plus ≥1 additional cardiometabolic risk factor(s)
  3. Patients with persistently elevated liver enzymes

This two-tier risk stratification approach (simple scores followed by elastography for indeterminate/high scores) has been validated as the most accurate method for diagnosing advanced fibrosis 3, balancing cost-effectiveness with diagnostic accuracy in real-world clinical practice.

References

Related Questions

What is the Fibrosis‑4 (FIB‑4) index, how is it calculated, and how are its results interpreted?
What is the difference between the Fibrosis-4 (FIB-4) index and the NASH/FibroSure test for hepatic steatosis?
What are the FIB‑4 score thresholds that define low, intermediate, and high risk for significant or advanced fibrosis?
What does a Fibrosis‑4 (FIB‑4) score of 1.63 indicate and what are the recommended next steps?
What is the Fib‑4 score for a 54‑year‑old patient with ALT 38 U/L, AST 37 U/L, and platelet count 150 000/µL?
Should a patient with atrial fibrillation who has undergone left atrial resection and has a CHA2DS2‑VASc score of 5 continue anticoagulation?
What are the indications, dosing regimens, contraindications, common adverse effects, and alternative therapies for GLP‑1 receptor agonists?
What are the causes of Candida esophagitis?
Is it safe to start metformin when the alanine aminotransferase (ALT) is 125 U/L?
What could cause a pulsating sensation over the right temple accompanied by headache and sinus pressure?
How should I manage a patient with major depressive disorder and anxiety who is taking venlafaxine 225 mg daily and aripiprazole (Abilify) 10 mg daily but continues to have moderate depression and anxiety with blood‑pressure spikes during panic attacks?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.